司美格鲁肽在肥胖相关射血分数保留心衰中的疗效性别差异:STEP-HFpEF试验
本研究为STEP-HFpEF和STEP-HFpEF DM两项试验的预设汇总分析,纳入1145例肥胖相关射血分数保留心衰患者,按性别比较司美格鲁肽2.4 mg每周一次与安慰剂的疗效。结果显示司美格鲁肽改善KCCQ-CSS和6分钟步行距离的效应无性别差异,但女性体重下降幅度更大。
要点
- 司美格鲁肽改善心衰症状和运动功能的效果不因性别而异。
- 女性使用司美格鲁肽后体重下降幅度大于男性。
- 司美格鲁肽在两种性别中均减少严重不良事件。
核心结论
- 在肥胖相关HFpEF患者中,司美格鲁肽2.4 mg在女性中减重更明显,但对心衰相关症状、体力限制和运动功能的改善在两性间相似。
研究设计与样本
- 预设的STEP-HFpEF和STEP-HFpEF DM试验汇总二次分析,纳入心衰、左室射血分数≥45%、体重指数≥30 kg/m2且KCCQ-CSS<90分的患者,随机1:1接受每周一次司美格鲁肽2.4 mg或匹配安慰剂治疗52周。
- 共纳入1145例患者,其中女性570例(49.7%)。
主要发现
- 司美格鲁肽改善KCCQ-CSS无性别差异:女性平均差异+7.6分(95%CI 4.5-10.7),男性+7.5分(95%CI 4.3-10.6),P交互=0.94。
- 司美格鲁肽减轻体重在女性中更明显:女性平均差异-9.6%(95%CI -10.9%至-8.4%),男性-7.2%(95%CI -8.4%至-6.0%),P交互=0.006。
- 司美格鲁肽改善6分钟步行距离(P交互=0.21)和分层复合终点(P交互=0.66)在两性中均一致。
- 司美格鲁肽组严重不良事件少于安慰剂组。
临床怎么用
- 对于肥胖相关HFpEF患者,司美格鲁肽2.4 mg可作为改善心衰症状和运动功能的治疗选择,疗效不受性别影响。
- 女性患者使用司美格鲁肽可能获得更显著的减重效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: More women than men have heart failure with preserved ejection fraction (HFpEF). OBJECTIVES: The purpose of this study was to assess baseline characteristics and treatment effect of semaglutide by sex across the STEP-HFpEF (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity) program. METHODS: In a prespecified secondary analysis of pooled data from STEP-HFpEF and STEP-HFpEF DM (Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes), patients with heart failure (HF), left ventricular ejection fraction ≥45%, body mass index ≥30 kg/m2, and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) <90 points were randomized 1:1 to once-weekly semaglutide 2.4 mg or matched placebo for 52 weeks. Dual primary endpoints (KCCQ-CSS change and percentage change in body weight) and confirmatory secondary endpoints (6-minute walking distance [6MWD] change; hierarchical composite endpoint comprising all-cause death, HF events, changes in KCCQ-CSS, and 6MWD; and C-reactive protein) were compared between sexes. RESULTS: Of 1,145 patients, 570 (49.7%) were women. Women had higher body mass index, left ventricular ejection fraction, C-reactive protein, and worse HF symptoms, and were less likely to have atrial fibrillation or coronary artery disease vs men. Semaglutide improved KCCQ-CSS regardless of sex (mean difference in women +7.6 points [95% CI: 4.5-10.7 points]; men +7.5 points [95% CI: 4.3-10.6 points]; P interaction = 0.94) but reduced body weight more in women (mean difference in women -9.6% [95% CI: -10.9% to -8.4%]; men -7.2% [95% CI: -8.4% to -6.0%]; P interaction = 0.006). Semaglutide improved 6MWD (P interaction = 0.21) and the hierarchical composite endpoint (P interaction = 0.66) in both sexes. Fewer serious adverse events were reported with semaglutide vs placebo. CONCLUSIONS: In patients with obesity-related HFpEF, semaglutide 2.4 mg reduced body weight to a greater extent in women, and produced similar improvements in HF-related symptoms, physical limitations, and exercise function, regardless of sex. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511; and Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP HFpEF DM]; NCT04916470).
引用
- Verma, Butler, Borlaug, et al. Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials. J Am Coll Cardiol. 2024. PMID: 38913003. doi:10.1016/j.jacc.2024.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。